What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?

Jose De Leon, Edoardo Spina

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


This editorial considers two questions in psychopharmacotherapy: 1) What is needed to market pharmacogenetic tests in the US, since the US appears to lead other countries? and 2) What is needed for US-marketed pharmacogenetic tests to be incorporated by prescribers into long-term practice? US marketing of pharmacogenetic tests requires 1) understanding the pharmacological complexity of drug response, 2) modifying the oversight of non-FDA regulatory agencies, 3) clarifying the FDAs role and 4) promoting innovative marketing. The incorporation of pharmacogenetic tests into long-term practice requires 1) not jeopardizing pharmacogenetic testing by short-sighted marketing of non-validated tests, 2) educating prescribers about benefits, 3) educating patients about limitations and 4) considering the differences between isolated testing and generalized testing incorporating big data.

Original languageEnglish
Pages (from-to)351-354
Number of pages4
JournalExpert Review of Clinical Pharmacology
Issue number3
StatePublished - Mar 3 2016

Bibliographical note

Publisher Copyright:
© 2015 Taylor & Francis.


  • Biological markers
  • United States Food and Drug Administration
  • cytochrome P-450 enzyme system/genetics
  • genotype
  • histocompatibility testing
  • pharmacogenetics
  • psychotropic drugs/administration and dosages

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics (all)
  • Pharmacology (medical)


Dive into the research topics of 'What is needed to incorporate clinical pharmacogenetic tests into the practice of psychopharmacotherapy?'. Together they form a unique fingerprint.

Cite this